AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
a study on Atrial Fibrillation Heart Conditions
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.
Official Title
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery
Details
The AtriCure CryoICE Ablation System is being studied to ablate cardiac tissue during surgery for the treatment of Persistent and Long-standing Persistent atrial fibrillation in open concomitant cardiac surgery.
The effectiveness of the device will be demonstrated by establishing that the device effectively eliminates persistent and long-standing persistent atrial fibrillation in a clinically significant proportion of treated patients.
Keywords
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation, Atrial Fibrillation, AtriCure CryoICE & AtriClip LAA Exclusion
Eligibility
You can join if…
Open to people ages 18 years and up
- Subject is greater than or equal to 18 years of age
- Subject has history of persistent or long-standing persistent atrial fibrillation as defined by the 2017 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/ European Cardiac Arrhythmia Society (ECAS) Guidelines
- Stable Subject that is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or replacement, and Coronary artery bypass procedures
- Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
- Subject is willing and able to provide written informed consent
- Subject has a life expectancy of at least 5 years
- Subject is willing and able to return for scheduled follow-up visits.
You CAN'T join if...
- Stand-alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery
- Previous surgical Maze procedure
- Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, Atrioventricular (AV) nodal reentry
- Prior cardiac surgery (Redo)
- Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or patent foramen ovale repair, and/or atrial septal defect repair.
- Class IV New York Heart Association (NYHA) heart failure symptoms
- Prior history of cerebrovascular accident within 6 months or at any time if there is residual neurological deficit
- Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
- Need for emergent cardiac surgery (i.e. cardiogenic shock)
- Known carotid artery stenosis greater than 80%
- Documented AF duration of greater than ten years
- LA diameter >7 cm by Transthoracic echocardiography (TTE)
- Current diagnosis of active systemic infection
- Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
- Renal failure requiring dialysis or hepatic failure
- A known drug and/or alcohol addiction
- Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study
- Pregnancy or desire to get pregnant within 12-months of the study treatment
- Preoperative need for an intra-aortic balloon pump or intravenous inotropes
- Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia
- Subjects who have been treated with thoracic radiation
- Subjects in current chemotherapy
- Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases)
- Subjects with known connective tissue disorders
- Subjects with known hypertrophic obstructive cardiomyopathy
- Subjects with known cold agglutinin
Locations
- UCLA Medical Center
Los Angeles California 90095 United States - St. Luke's Hospital
Kansas City Missouri 64111 United States
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AtriCure, Inc.
- ID
- NCT03732794
- Study Type
- Interventional
- Participants
- About 150 people participating
- Last Updated